ライフサイエンスコーパス: exercise tolerance

1 to restrict motor unit activation and limit exercise tolerance.

2 vascular rarefaction may be key to restoring exercise tolerance.

3 ificant improvements in angina frequency and exercise tolerance.

4 duced muscle oxidative function and impaired exercise tolerance.

5 pact on ventricular volume and function, and exercise tolerance.

6 h and nine studies examining their effect on exercise tolerance.

7 a deficit in AMPK activity markedly impairs exercise tolerance.

8 pulmonary neutrophilia and the reduction in exercise tolerance.

9 nd leads to an improvement in LV filling and exercise tolerance.

10 Patients with HOCM have reduced exercise tolerance.

11 tion of iron might improve both symptoms and exercise tolerance.

12 or did it decrease cardiomyopathy or restore exercise tolerance.

13 eceptor antagonists abolished differences in exercise tolerance.

14 urthermore, it reduces symptoms and improves exercise tolerance.

15 ansport and utilization of O(2), diminishing exercise tolerance.

16 > or =10 have objective evidence of reduced exercise tolerance.

17 low relaxation and E/Ea > or =10 had reduced exercise tolerance.

18 ostcontraction vasodilatation may compromise exercise tolerance.

19 , Canadian Cardiovascular Society class, and exercise tolerance.

20 k of death or MI, but it improved angina and exercise tolerance.

21 y disease (CAD), more severe CAD and a lower exercise tolerance.

22 implications for novel therapies to improve exercise tolerance.

23 ant of exercise hyperventilation and reduced exercise tolerance.

24 f (VE/VCO(2)) in CHF patients with preserved exercise tolerance.

25 ack restrict motor unit activation and limit exercise tolerance.

26 entral role in the control of metabolism and exercise tolerance.

27 itical speed) was used to evaluate treadmill exercise tolerance.

28 endothelin receptor expression and impaired exercise tolerance.

29 atients with known or suspected CAD and high exercise tolerance.

30 le, objective, and physiologic expression of exercise tolerance.

31 fore and after the operation showed improved exercise tolerance.

32 lower V(E); this is associated with improved exercise tolerance.

33 an presented with palpitations and decreased exercise tolerance.

34 on for Ebstein's anomaly results in improved exercise tolerance.

35 subgroup with symptomatic ischemia and poor exercise tolerance.

36 ronic diabetic neuropathic pain and improves exercise tolerance.

37 ing to short-term improvement in dyspnea and exercise tolerance.

38 mic responsiveness, while increasing maximal exercise tolerance.

39 acco history developed a cough and decreased exercise tolerance.

40 dividuals with desensitized B-ARs or limited exercise tolerance.

41 muscle blood flow during exercise, hindering exercise tolerance.

42 either unable to exercise or have a very low exercise tolerance.

43 ance, shortness of breath, and reductions in exercise tolerance.

44 ad no respiratory symptoms, and enjoyed good exercise tolerance.

45 zed by pain, decline in function and reduced exercise tolerance.

46 task-dependent nature of mechanisms limiting exercise tolerance.

47 iated with reduced systolic augmentation and exercise tolerance.

48 contribution to ATP synthesis, and increased exercise tolerance.

49 altered haemoglobin affinity impacts hypoxic exercise tolerance.

50 nt in left ventricular ejection fraction and exercise tolerance.

51 ked sarcolemmal fragility and reduced muscle exercise tolerance.

52 at rest occur in conjunction with excellent exercise tolerance.

53 ible benefits to reduce symptoms and improve exercise tolerance.

54 rgement, impaired lung function, and reduced exercise tolerance.

55 oxidative myofibers, muscle vasculature, and exercise tolerance (33%) are decreased in mdx vs. wild-t

56 ), cough (45%), fatigue (45%), and decreased exercise tolerance (45%).

57 ion group than in the medical-therapy group (exercise tolerance, 5.0 MET [metabolic equivalent] vs. 3

58 1), arterial partial pressure of oxygen, and exercise tolerance 6 months after surgery.

59 Increase in exercise tolerance (6 min walk distance) was a potent me

60 Improvements in exercise tolerance (8 of 10 patients), EF (19 +/- 13%, p

61 There was better exercise tolerance (9.3+/-2.0 versus 7.3+/-3.1 minutes,

62 Additionally, IG KO mice have a reduced exercise tolerance, a phenotype often associated with di

63 etal muscle function, which led to increased exercise tolerance, activation of FAPs, facilitation of

64 All 5 living patients returned to baseline exercise tolerance after 6 to 16 weeks of follow-up.

65 fety of exercise provocation tests to assess exercise tolerance after consumption of allergens follow

66 nexplained exertional dyspnea and diminished exercise tolerance after deployment, an analysis of biop

67 Both groups had a higher exercise tolerance after training and when breathing oxy

68 substantial relief of symptoms and improved exercise tolerance and also showed reduced or abolished

69 ults highlight a critical role for TBC1D1 in exercise tolerance and contraction-mediated translocatio

70 tors responsible for development of impaired exercise tolerance and disease progression are incomplet

71 TGA patients have limited exercise tolerance and early mortality due to systemic (

72 cular weight adiponectin levels and improved exercise tolerance and energy expenditure.

73 ues to show promise as a method of improving exercise tolerance and enhancing oxidative capacity.

74 hypertensive response to exercise, increases exercise tolerance and improves quality of life.

75 horacic radiation therapy (RT) have impaired exercise tolerance and increased cardiovascular mortalit

76 te that targeted inhibition of Fn14 improves exercise tolerance and inhibits denervation-induced musc

77 llbeing, but molecular mechanisms underlying exercise tolerance and its plasticity are only partially

78 -dose nitrate therapy significantly improves exercise tolerance and left ventricular size and systoli

79 ble long-term benefit was a trend for better exercise tolerance and less depression of quality of lif

80 Therefore, increases in exercise tolerance and muscle adaptations are not impair

81 tion showed functional impairment (decreased exercise tolerance and muscle strength) in APP(SWE)/PS1

82 Exercise tolerance and New York Heart Association class

83 tion during exercise in hypoxia and restored exercise tolerance and oxidative function to values obse

84 (large ES); antidepressants were neutral on exercise tolerance and PHQoL.

85 We determined the effect on exercise tolerance and physiological exercise responses

86 es may help develop strategies for improving exercise tolerance and preventing heat injury.

87 lated lipid metabolism, leading to increased exercise tolerance and protection against diet-induced o

88 Improved exercise tolerance and quality of life have been demonst

89 f intravenous iron found improved short-term exercise tolerance and quality of life in patients with

90 perfusion defects, as well as with enhanced exercise tolerance and quality of life.

91 udy of two weeks of losartan (50 mg q.d.) on exercise tolerance and quality of life.

92 persist, but felodipine prevented worsening exercise tolerance and quality of life.

93 Exercise tolerance and quality-of-life scores were also

94 tricular resection, including reduced animal exercise tolerance and sudden death in the setting of st

95 hese observations may play a role in reduced exercise tolerance and tachycardia-induced diastolic dys

96 dine produces dose-dependent improvements in exercise tolerance and time to development of ischemia d

97 rease in QRS duration and a deterioration of exercise tolerance and ventricular dysfunction did not p

98 which could be utilized by patients with low exercise tolerance and/or capabilities.

99 populations, particularly those with limited exercise tolerance and/or capabilities.

100 e abnormalities are associated with impaired exercise tolerance, and abnormal HRR predicts increased

101 anadian Cardiovascular Society angina class, exercise tolerance, and antianginal medications), myocar

102 anadian Cardiovascular Society angina class, exercise tolerance, and antianginal medications).

103 pathy (MM) associated with varying levels of exercise tolerance, and compared responses with those in

104 nge, resulting in breathlessness, diminished exercise tolerance, and decreased quality of life.

105 put, and resulted in weight loss, diminished exercise tolerance, and enhanced susceptibility to induc

106 Data including functional class, exercise tolerance, and hemodynamics were recorded in a

107 uced left ventricular hypertrophy, increased exercise tolerance, and improved quality of life, the op

108 ted with reduced diastolic function, reduced exercise tolerance, and increased pulmonary congestion a

109 lated with poor functional status, decreased exercise tolerance, and invasive hemodynamics variables.

110 ed with less pulmonary regurgitation, better exercise tolerance, and less QRS prolongation and sympto

111 sociated with improved ventricular function, exercise tolerance, and long-term survival in patients w

112 o have abnormal lung function tests, reduced exercise tolerance, and may be at increased risk for dev

113 in preclinical models and improves symptoms, exercise tolerance, and mortality in refractory angina p

114 reduction in anginal symptoms, increases in exercise tolerance, and objective improvements in myocar

115 Activity level, exercise tolerance, and orthostatic testing could not di

116 al considerations, such as patient symptoms, exercise tolerance, and patient preference.

117 progression, as reflected by lung function, exercise tolerance, and progression-free survival, in pa

118 ostacyclin, PGI2) improves haemodynamics and exercise tolerance, and prolongs survival in severe PPH

119 F levels, impaired cardiac function, reduced exercise tolerance, and pulmonary oedema; PAD4-/- mice w

120 s left ventricular ejection fraction (LVEF), exercise tolerance, and quality of life among patients w

121 aningful benefits in lung function, dyspnea, exercise tolerance, and quality of life, with an accepta

122 fraction, New York Heart Association class, exercise tolerance, and quality of life.

123 aningful benefits of improved lung function, exercise tolerance, and quality of life.

124 blood analyses, pulmonary function testing, exercise tolerance, and quality-of-life assessment at 0,

125 in skeletal muscle mitochondrial biogenesis, exercise tolerance, and response to exercise training.

126 rovements in heart failure-related symptoms, exercise tolerance, and reversal of ventricular remodeli

127 m bacterial densities, inflammatory markers, exercise tolerance, and subjective well-being did not ch

128 nduced modest improvements in lung function, exercise tolerance, and symptoms at the cost of more fre

129 s lung tissue and may improve lung function, exercise tolerance, and symptoms in patients with emphys

130 lysis, impaired cardiac function and reduced exercise tolerance, and that the level of altitude would

131 exacerbations, weight gain, quality of life, exercise tolerance, and the total costs of hospital and

132 ysfunction are associated with impairment in exercise tolerance as assessed by peak oxygen consumptio

133 ttle Angina Questionnaire and improvement in exercise tolerance as assessed by treadmill exercise tes

134 s outpatients for assessment of symptoms and exercise tolerance as measured by change in the NYHA cla

135 that lung volume reduction surgery improves exercise tolerance as measured by the 6-min walk distanc

136 These changes affect exercise tolerance, as indicated by the positive correla

137 Exercise training improved exercise tolerance, as measured by increases in peak VO2

138 Exercise tolerance at 12 months had increased by a media

139 The primary endpoint was the exercise tolerance at 12 months.

140 hanges in lung function, quality of life, or exercise tolerance between roflumilast- and placebo-trea

141 umber of clinical parameters, lung function, exercise tolerance, biomarkers, and amount of emphysema

142 on of MP fusion 4 weeks into HIIT, preserved exercise tolerance but attenuated hypertrophy.

143 psychosocial support, improves symptoms and exercise tolerance but is underutilized.

144 d QRS duration were univariate predictors of exercise tolerance, but only t-IVT and CAD were independ

145 s is thought to contribute to a reduction in exercise tolerance, but the relative contribution of a c

146 Limitation of exercise tolerance by dyspnea is common in the elderly a

147 ure, and blood flow (by 33-66%) and improved exercise tolerance (by 75%) in the dystrophic mice.

148 The impact of these constraints on exercise tolerance cannot be determined from this invest

149 included functional class and improvement in exercise tolerance, cardiac index, and mean pulmonary ar

150 Finally, Tyk2(-/-) mice show decreased exercise tolerance compared to wild-type littermates.

151 ores for a given work rate leading to poorer exercise tolerance compared with their counterparts (P <

152 nts with ERVSP > or = 40 mm Hg had decreased exercise tolerance compared with those with ERVSP <40 mm

153 rachial index, forced expiratory volume, and exercise tolerance, did not change the results.

154 roved collateral vessel function and enhance exercise tolerance during routine physical activity.

155 dily implementable approaches for evaluating exercise tolerance enabling exercise prescriptions at ap

156 d desaturation, we evaluated improvements in exercise tolerance facilitated by a wearable, 1-lb, noni

157 m to be required for body weight regulation, exercise tolerance, fatty acid oxidation, or cold-induce

158 r patients have had sustained improvement in exercise tolerance, from 3.5 mo to 4.5 yr after stent pl

159 Baseline predictors of survival included exercise tolerance, functional class, right atrial press

160 most instances, an associated improvement in exercise tolerance has been reported.

161 erfusion imaging (MPI) in patients with high exercise tolerance has not been established.

162 The role of miR-133a in exercise tolerance has not been fully elucidated.

163 erobic capacity ( V O(2) max) and submaximal exercise tolerance (i.e. speed-duration relationship) du

164 Cardiac symptoms and exercise tolerance improved from baseline to a similar d

165 ease co-morbidities, will assist recovery of exercise tolerance in a variety of conditions that limit

166 he hypothesis that intravenous iron improves exercise tolerance in anemic and nonanemic patients with

167 both TKO and TXNIP(SKM-/-) mice had reduced exercise tolerance in association with muscle-specific i

168 on is hypothesized to contribute to impaired exercise tolerance in cardiovascular disease, but it rem

169 ACE DD genotype is associated with decreased exercise tolerance in CHF, possibly mediated by altered

170 -talk could benefit muscle bioenergetics and exercise tolerance in conditions like obesity.

171 prominently, CAD, are major determinants of exercise tolerance in DCM.

172 n vivo, which has important implications for exercise tolerance in health and certain disease states

173 ular K(ATP) channels help sustain submaximal exercise tolerance in healthy rats.

174 imulator, vericiguat, on quality of life and exercise tolerance in heart failure patients with preser

175 hether chronotropic incompetence and reduced exercise tolerance in HF are attributable to beta-blocka

176 Finally, we observed that exercise tolerance in HF rats was related to carotid bod

177 Oxygen therapy improves submaximal exercise tolerance in hypoxemic patients with chronic ob

178 training intensity and evidence of gains in exercise tolerance in laboratory testing.

179 ing in "leaky" channels that cause decreased exercise tolerance in mice.

180 (The Influence of Heart Rate Limitation on Exercise Tolerance in Pacemaker Patients [TREPPE]; NCT02

181 indings may have widespread implications for exercise tolerance in patient populations who experience

182 Spinal anesthesia enhanced cycling exercise tolerance in patients with COPD, mostly by redu

183 We assessed the effect of losmapimod on exercise tolerance in patients with COPD.

184 giotensin II (Ang II) blockade would improve exercise tolerance in patients with diastolic dysfunctio

185 is study was to identify the determinants of exercise tolerance in patients with Ebstein's anomaly.

186 fferent rate or rhythm control strategies on exercise tolerance in patients with HFpEF and AF is warr

187 e mechanisms linking dynamic obstruction and exercise tolerance in patients with hypertrophic obstruc

188 e that may thereby improve lung function and exercise tolerance in patients with pulmonary hyperinfla

189 ernal counterpulsation improves symptoms and exercise tolerance in patients with symptomatic coronary

190 eintroduced to alleviate dyspnea and improve exercise tolerance in selected patients with emphysema.

191 oplasty may improve flow rates, comfort, and exercise tolerance in severe emphysema.

192 supplementation on endothelial function and exercise tolerance in stable coronary artery disease (CA

193 We hypothesized that good exercise tolerance in such patients treated medically is

194 ting demonstrated significant improvement in exercise tolerance in TAC/DOCA mice that expressed N2BAs

195 itins, which improves diastolic function and exercise tolerance in the TAC/DOCA model.

196 pact on operating lung volumes, dyspnea, and exercise tolerance in these patients.

197 ated and comparable to enalapril in terms of exercise tolerance in this short-term (12-week) study of

198 in immunofluorescence assays (P < 0.05) and exercise tolerance in treadmill tests (P < 0.05), wherea

199 g allograft dysfunction can be subdivided by exercise tolerance in two groups, and quality of life (Q

200 At 12 months, total exercise tolerance increased by a median of 65 s in the

201 s been independently associated with reduced exercise tolerance, increased heart failure hospitalizat

202 RV dysfunction impairs exercise tolerance independent of LV dysfunction.

203 in GLUT4(-/-)HK(Tg) show that HK II improves exercise tolerance, independent of its effects on MGU.

204 Although high exercise tolerance is associated with an excellent progn

205 Exercise tolerance is decreased in patients with pulmona

206 ay, therefore, dictate intensities for which exercise tolerance is determined by the magnitude of fat

207 In addition, dyspnea is lessened, exercise tolerance is increased, and measured pulmonary

208 Maximal exercise tolerance is reduced in PPH, but gas exchange r

209 he age of 3-4 mo, and maximal stress-induced exercise tolerance is reduced, indicating impaired physi

210 or heart responds abnormally to exercise and exercise tolerance is reduced.

211 therapy, improves symptoms, quality of life, exercise tolerance, left ventricular function, and the s

212 gly, we hypothesized that pacing may improve exercise tolerance long-term in this syndrome.

213 During the 12-month intervention, exercise tolerance (maximum treadmill workload and 6-min

214 dvanced lung allograft dysfunction regarding exercise tolerance might result from altered IC and impa

215 Impaired exercise tolerance, mitochondrial biogenesis, and muscle

216 After 6 weeks, exercise tolerance, myocardial function, and end-organ f

217 Improvement in symptoms and exercise tolerance occurred in all patients, and a signi

218 Supplemental oxygen improves exercise tolerance of normoxemic and hypoxemic chronic o

219 Losmapimod did not cause an improvement in exercise tolerance or lung function, despite being well-

220 acoronary infusion of rFGF2 does not improve exercise tolerance or myocardial perfusion but does show

221 ng: an improvement of at least 25 percent in exercise tolerance or pulmonary-function tests or resolu

222 res of patient benefit, including changes in exercise tolerance or quality-of-life scores.

223 ed with a greater improvement in symptoms or exercise tolerance or with a reduction in the rate of de

224 erance, such as advanced age, diabetes, poor exercise tolerance, or history of myocardial infarctions

225 oxygen saturation is the major predictor of exercise tolerance, oxygen saturation at peak exercise a

226 ith reduced muscle mass, abnormal indexes of exercise tolerance (peak V(O2), V(E)/V(CO2) slope), ejec

227 ymptomatic state (NYHA class, P<0.05), lower exercise tolerance (peak VO(2), P<0.05), and pronounced

228 Substudies included exercise tolerance, plasma hormone and cytokines, echoca

229 costs of chronic inflammation and to foster exercise tolerance provide a rationale for therapeutic u

230 rtant clinical implications, such as reduced exercise tolerance, quality of life, and even survival.

231 domized, single-blinded study, EECP improved exercise tolerance, quality of life, and NYHA functional

232 he placebo group, P=.01) but did not improve exercise tolerance, quality of life, or the need for hos

233 ideline included mortality; hospitalization; exercise tolerance; quality of life; and cardiovascular

234 patients with otherwise unexplained impaired exercise tolerance; recurrent lower airways infection; a

235 Exercise tolerance reflects the integrative capacity of

236 Baseline assessments were angina class, exercise tolerance, Seattle angina questionnaire for qua

237 Exercise tolerance significantly improved at 3 months (n

238 y class (MD, -0.58; 95% CI, -1.00 to -0.16), exercise tolerance (standardized MD, 0.331; 95% CI, 0.08

239 in brachial artery endothelial function and exercise tolerance, suggesting a potential mechanism by

240 py use from baseline for pulmonary function, exercise tolerance, survival, hospital admission, and ad

241 Demographics, spirometry, exercise tolerance, symptom questionnaires, CFTR genetic

242 Case series have shown that EECP can improve exercise tolerance, symptoms and myocardial perfusion in

243 Noninvasive stress imaging or an exercise tolerance test (ETT) are the most common method

244 a and enhances functional capacity during an exercise tolerance test (ETT) in patients with coronary

245 on or myocardial infarction (MI), with a pre-exercise tolerance test (ETT) likelihood of CAD > or =0.

246 postinfarction angina or a strongly positive exercise tolerance test (ETT) typically had cost-effecti

247 , exercise, and nuclear models by use of pre-exercise tolerance test (ETT), post-ETT, and nuclear inf

248 netic resonance imaging (n=108; r=0.31), and exercise tolerance test (n=1134; r=0.18).

249 , CA, and Washington DC, USA, who had had an exercise tolerance test between 1986, and 2011.

250 Deterioration in all exercise tolerance test parameters occurred in patients

251 s were similar in the 2 approaches, with the exercise tolerance test result exerting the greatest lev

252 cumented coronary artery disease, a positive exercise tolerance test, and stable chronic angina pecto

253 Efficacy was evaluated at 90 and 180 days by exercise tolerance test, myocardial nuclear perfusion im

254 ac magnetic resonance imaging, or nonimaging exercise tolerance test.

255 depression > or =1 mm from baseline) during exercise tolerance testing (ETT) was examined in patient

256 dical treatment and, if stable, predischarge exercise tolerance testing (n = 1106).

257 principally in middle-aged men, suggest that exercise tolerance testing can provide independent progn

258 Although screening exercise tolerance testing detects severe coronary arter

259 Exercise tolerance testing has been proposed as a means

260 le cohort studies demonstrate that screening exercise tolerance testing identifies a small proportion

261 ta-blocker therapy underwent cardiopulmonary exercise tolerance testing under 2 conditions in random

262 disease events (relative risk with abnormal exercise tolerance testing, 2.0 to 5.0).

263 nsional echocardiography, Holter monitoring, exercise tolerance testing, and ajmaline provocation.

264 ography, cardiac magnetic resonance imaging, exercise tolerance testing, and biomarker assessment.

265 chocardiography, magnetic resonance imaging, exercise tolerance testing, n=5105, 99%).

266 d point but not after adjusting for positive exercise tolerance testing.

267 dulthood caused male mice to underperform at exercise tolerance tests compared to their control and f

268 to limiting angina during bicycle exercise (exercise tolerance tests), performed at trough of drug a

269 musclin secretion in mice results in reduced exercise tolerance that can be rescued by treatment with

270 al care resulted in an improvement in median exercise tolerance that was modest and of uncertain clin

271 th chronic heart failure (CHF) and preserved exercise tolerance, the value of cardiopulmonary exercis

272 - 0.8 mo) showed significant improvements in exercise tolerance: The distance covered over a 6 min wa

273 to guide management of patients with limited exercise tolerance, those at highest risk for perioperat

274 TMR lowered angina scores, increased exercise tolerance time, and improved patients' percepti

275 PTMR was associated with increased exercise tolerance time, low morbidity, lower angina sco

276 stress allows an assessment of the patient's exercise tolerance, to be performed while adequately str

277 ly associated with decreased muscle mass and exercise tolerance; untreated LH/FSHD was associated wit

278 Exercise tolerance using a bicycle ergometer showed incr

279 Exercise tolerance was assessed on a treadmill.

280 This improved exercise tolerance was caused in part by an increase in

281 f patients were relieved of angina symptoms, exercise tolerance was improved, complications were mini

282 Exercise tolerance was increased at 90 days in all group

283 Exercise tolerance was not significantly different betwe

284 Exercise tolerance was observed.

285 Exercise tolerance was reduced in GLUT4(-/-) compared to

286 Similarly, improvement in exercise tolerance was significantly greater in low-dose

287 In vivo, maximal exercise tolerance was significantly impaired only in I7

288 and hypoxic (HVR) ventilatory responses, and exercise tolerance were assessed at the end of a 6 week

289 nflammation, lung mechanical properties, and exercise tolerance were determined at different time poi

290 ion, and subjective and objective changes in exercise tolerance were end points.

291 Chronic cough and reduced exercise tolerance were reported by 66% and 21% of parti

292 The F110I mutation impaired acute exercise tolerance, whereas R278C did not.

293 Pulmonary hypertension (PH) impairs exercise tolerance, which is associated with skeletal an

294 tory muscle oxygen delivery and compromising exercise tolerance, which may be improved by therapeutic

295 ng patients in the assessment of symptoms or exercise tolerance while expanding the range of patients

296 often performed in stable patients with good exercise tolerance who have not been treated with proven

297 These results suggest that (1) exercise tolerance with COPD is limited by dynamic hyper

298 ion) and 60 patients with stage B HF (normal exercise tolerance with left ventricular hypertrophy, an

299 ior pilot studies have shown improvements in exercise tolerance with single-dose and short-term inorg

300 s with elevated HDGF had significantly lower exercise tolerance, worse New York Heart Association fun